Mitochondrial
health research
Explore the research on NMN, mitophagy, NAD⁺ metabolism and more.
The studies do not establish a human lifespan benefit.
Human data exists, but no mitochondrial intervention has a healthy-aging lifespan RCT. The human evidence here is functional (muscle/vascular), biomarker (NAD⁺, immune), or disease-outcome (CoQ10 mortality in heart failure; elamipretide approved for the rare disease Barth syndrome) — never a healthy-aging lifespan trial. "Improves a biomarker in a trial" ≠ "extends healthy human lifespan," and "reduces mortality in heart failure" ≠ "anti-aging."
Interventions
Urolithin A
Gut-microbiome metabolite; mitophagy activatorMitoQ (mitoquinone)
Mitochondria-targeted antioxidant (mtROS)Nicotinamide riboside (NR)
NAD⁺ precursorNicotinamide mononucleotide (NMN)
NAD⁺ precursorCoenzyme Q10 / ubiquinol
Electron carrier / antioxidantElamipretide (SS-31)
Cardiolipin-binding tetrapeptidePQQ (pyrroloquinoline quinone)
Claimed mitochondrial-biogenesis cofactorStudies
Urolithin A first-in-human: safety and a mitochondrial gene signature (Andreux et al., 2019)
Human RCT — biomarker endpointUrolithin A: secondary muscle-strength improvement, primary peak-power endpoint not met (Singh et al., 2022)
Human RCT — functional endpointUrolithin A and muscle endurance in older adults, 65-90 (Liu et al., 2022)
Human RCT — functional endpointUrolithin A and immune-cell biomarkers in healthy adults aged 45–70 (Denk et al., 2025)
Human RCT — biomarker endpointMitoQ improves vascular function in healthy older adults (Rossman et al., 2018)
Human RCT — functional endpointChronic nicotinamide riboside elevates NAD⁺ in healthy adults (Martens et al., 2018)
Human RCT — biomarker endpointNMN, NAD⁺ metabolism, and arterial stiffness (2023)
Human RCT — biomarker endpointQ-SYMBIO: CoQ10 reduces mortality in chronic heart failure (Mortensen et al., 2014)
Human clinical-outcome RCT — disease populationMMPOWER-3: elamipretide Phase 3 in primary mitochondrial myopathy — failed primary (Karaa et al., 2023)
Human RCT — functional endpoint (failed)Urolithin A induces mitophagy and prolongs lifespan in C. elegans and improves rodent muscle (Ryu et al., 2016)
Animal healthspan / lifespan studyNMN and glucose/lipid metabolism: no significant pooled effect in a meta-analysis (2024/2025)
Human RCT — biomarker endpoint (meta-analysis, null)Mechanisms
Mitochondrial dysfunction as a hallmark of aging
Causal-framing conceptCellular respiration / OXPHOS
Core functionMitophagy (PINK1 / Parkin)
Quality-control pathwayMitochondrial biogenesis (PGC-1α)
Turnover / growth pathwayMitochondrial reactive oxygen species (mtROS)
Signalling / damage nodeNAD⁺ metabolism
Cofactor / signalling pathwayCardiolipin
Inner-membrane lipidMitochondrial dynamics (fission / fusion)
Network quality controlMitochondrial unfolded-protein response (UPRmt)
Stress-signalling pathwayEvidence tiers
| Tier | Label | Note |
|---|---|---|
| 1 | Healthy-aging human lifespan RCT | Randomized, hard lifespan/healthy-aging endpoint in a healthy-aging population. NONE exist for any mitochondrial intervention as of the search date — tier empty by design. |
| 2 | Human clinical-outcome RCT — disease population | Randomized, hard clinical outcome (e.g. mortality) but in a disease population, not healthy aging. Example: Q-SYMBIO CoQ10 mortality in chronic heart failure. |
| 3 | Human RCT — functional endpoint | Randomized, endpoint is a physical-function measure (muscle strength/endurance, VO2, vascular/endothelial function), not lifespan. |
| 4 | Human RCT — biomarker endpoint | Randomized, endpoint is a biomarker (NAD+, blood pressure, arterial stiffness, immune or gene-expression markers, lipids/glucose). |
| 5 | Human observational / mechanistic | Cohort, cross-sectional, or ex-vivo human tissue; no randomized intervention. |
| 6 | Animal healthspan / lifespan study | Lifespan or healthspan/function change in an animal or invertebrate model (e.g. urolithin A in C. elegans and rodents). |
| 7 | In vitro / mechanism | Cell-culture or biochemical mechanism; no whole-organism outcome. |